Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment-questions from the KRISTINE study

Jack P. Gleeson; Niamh M. Keegan; Patrick G. Morris

doi:10.21037/tcr.2018.04.14

Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment-questions from the KRISTINE study

Jack P. Gleeson
, Niamh M. Keegan
, Patrick G. Morris

Royal College of Surgeons in Ireland

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	S562-S567
Journal	Translational Cancer Research
Volume	7
DOIs	https://doi.org/10.21037/tcr.2018.04.14
Publication status	Published - 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.21037/tcr.2018.04.14

Cite this

@article{cb23877de5b74f63bc73b092a75059c7,

title = "Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment-questions from the KRISTINE study",

author = "Gleeson, \{Jack P.\} and Keegan, \{Niamh M.\} and Morris, \{Patrick G.\}",

year = "2018",

doi = "10.21037/tcr.2018.04.14",

language = "English",

volume = "7",

pages = "S562--S567",

journal = "Translational Cancer Research",

issn = "2218-676X",

publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment-questions from the KRISTINE study

AU - Gleeson, Jack P.

AU - Keegan, Niamh M.

AU - Morris, Patrick G.

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/pages/publications/85048211662

U2 - 10.21037/tcr.2018.04.14

DO - 10.21037/tcr.2018.04.14

M3 - Editorial

AN - SCOPUS:85048211662

SN - 2218-676X

VL - 7

SP - S562-S567

JO - Translational Cancer Research

JF - Translational Cancer Research

ER -

Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment-questions from the KRISTINE study

UN SDGs

Access to Document

Other files and links

Cite this